Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells

作者：Mordasini Vanessa; Ueda Seigo; Aslandogmus Roberta; Berger Christoph; Gysin Claudine; Huhn Daniela; Sartori Alessandro A; Bernasconi Michele; Nadal David^*

来源：Oncotarget, 2017, 8(4): 6461-6474.

DOI：10.18632/oncotarget.14120

• EBV
• DDR
• ATR
• Chk1
• hyperproliferation

Primary infection of the immunocompromised host with the oncovirus Epstein-Barr virus (EBV) that targets mainly B-cells is associated with an increased risk for EBV-associated tumors. The early events subsequent to primary infection with potential for B-cell transformation are poorly studied. Here, we modeled in vitro the primary infection by using B-cells isolated from tonsils, the portal of entry of EBV, since species specificity of EBV hampers modeling in experimental animals. Increasing evidence indicates that the host DNA damage response (DDR) can influence and be influenced by EBV infection. Thus, we inoculated tonsillar B-cells (TBCs) with EBV-B95.8 and investigated cell proliferation and the DDR during the first 96 hours thereafter. We identified for the first time that EBV infection of TBCs induces a period of hyperproliferation 48-96 hours post infection characterized by the activation of ataxia telangiectasia and Rad3-releated (ATR) and checkpoint kinase-1 (Chk1). Whereas inhibition of Chk1 did not affect B-cell transformation, the specific inhibition of ATR robustly decreased the transformation efficiency of EBV. Our results suggest that activation of ATR is key for EBV-induced B-cell transformation. Thus, targeting the interaction between ATR/Chk1 and EBV could offer new options for the treatment of EBV-associated malignancies.

• 出版日期2017-1-24